1301 related articles for article (PubMed ID: 31075726)
1. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
[TBL] [Abstract][Full Text] [Related]
3. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
[TBL] [Abstract][Full Text] [Related]
4. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
5. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
6. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.
Fitzgerald KN; Duzgol C; Knezevic A; Shapnik N; Kotecha R; Aggen DH; Carlo MI; Shah NJ; Voss MH; Feldman DR; Motzer RJ; Lee CH
Eur Urol; 2023 Mar; 83(3):195-199. PubMed ID: 36344318
[TBL] [Abstract][Full Text] [Related]
7. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
8. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.
Nadal R; Amin A; Geynisman DM; Voss MH; Weinstock M; Doyle J; Zhang Z; Viudez A; Plimack ER; McDermott DF; Motzer R; Rini B; Hammers HJ
Ann Oncol; 2016 Jul; 27(7):1304-11. PubMed ID: 27059553
[TBL] [Abstract][Full Text] [Related]
9. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
Yang Y; Psutka SP; Parikh AB; Li M; Collier K; Miah A; Mori SV; Hinkley M; Tykodi SS; Hall E; Thompson JA; Yin M
Cancer Med; 2022 Aug; 11(16):3106-3114. PubMed ID: 35304832
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
11. Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.
Wells JC; Dudani S; Gan CL; Stukalin I; Azad AA; Liow E; Donskov F; Yuasa T; Pal SK; De Velasco G; Hansen AR; Beuselinck B; Kollmannsberger CK; Powles T; McGregor BA; Duh MS; Huynh L; Heng DYC
Clin Genitourin Cancer; 2021 Aug; 19(4):354-361. PubMed ID: 33863648
[TBL] [Abstract][Full Text] [Related]
12. Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy.
Ishihara H; Kondo T; Yoshida K; Omae K; Takagi T; Iizuka J; Tanabe K
Urol Oncol; 2017 Sep; 35(9):542.e1-542.e9. PubMed ID: 28619633
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
14. Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.
Yan X; Zhou L; Li S; Wu X; Cui C; Chi Z; Si L; Kong Y; Tang B; Li C; Mao L; Wang X; Lian B; Bai X; Dai J; Guo J; Sheng X
Clin Genitourin Cancer; 2022 Aug; 20(4):354-362. PubMed ID: 35387755
[TBL] [Abstract][Full Text] [Related]
15. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.
Epaillard N; Simonaggio A; Elaidi R; Azzouz F; Braychenko E; Thibault C; Sun CM; Moreira M; Oudard S; Vano YA
Bull Cancer; 2020 Jun; 107(5S):eS22-eS27. PubMed ID: 32620212
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations.
Ged Y; Gupta R; Duzgol C; Knezevic A; Shapnik N; Kotecha R; Voss MH; Feldman DR; Akin O; Patil S; Motzer RJ; Rini BI; Lee CH
BMC Urol; 2020 Jul; 20(1):84. PubMed ID: 32616076
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
[TBL] [Abstract][Full Text] [Related]
18. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis.
Ciccarese C; Iacovelli R; Porta C; Procopio G; Bria E; Astore S; Cannella MA; Tortora G
Cancer Treat Rev; 2021 Nov; 100():102295. PubMed ID: 34564043
[TBL] [Abstract][Full Text] [Related]
20. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
